Table 1 Baseline characteristics of participants (ITT).
From: Randomized trial of influence of vitamin D on the prevention and improvement of symptomatic COVID-19
Vitamin D2 | Non-intervention | P | |
|---|---|---|---|
Age (years) | 36.76 ± 9.99 | 40.38 ± 11.52 | 0.018 |
Gender | 0.974 | ||
Female | 79 (79.8) | 82 (79.61) | |
Male | 20 (20.2) | 21 (20.39) | |
BMI (kg/m2) | 22.51 ± 2.79 | 23.63 ± 3.06 | 0.007 |
Serum 25(OH)D (ng/mL) | 14.1 (10.7, 17.3) | 14.4 (11.6, 18.3) | 0.892 |
CRP (mg/dL) | 0.27 (0.05, 0.9) | 0.46 (0.09, 1.48) | 0.089 |
C1q (mg/L) | 174 (163, 215) | 182 (163, 219) | 0.501 |
COVID-19 vaccines | 0.482 | ||
0 | 3 (3.03) | 1 (0.97) | |
1 | 0 (0) | 1 (0.97) | |
2 | 1 (1.01) | 4 (3.88) | |
3 | 63 (63.64) | 65 (63.11) | |
4 | 32 (32.32) | 32 (31.07) | |
Smoking | 0.724 | ||
No | 89 (89.9) | 91 (88.35) | |
Yes | 10 (10.1) | 12 (11.65) | |
Hypertension | 0.432 | ||
No | 94 (94.95) | 95 (92.23) | |
Yes | 5 (5.05) | 8 (7.77) | |
Diabetes | > 0.999 | ||
No | 97 (97.98) | 100 (97.09) | |
Yes | 2 (2.02) | 3 (2.91) | |
Coronary heart disease | 0.49 | ||
No | 98 (98.99) | 103 (100) | |
Yes | 1 (1.01) | 0 (0) | |
COPD | 0.49 | ||
No | 98 (98.99) | 103 (100) | |
Yes | 1 (1.01) | 0 (0) | |
Asthma | 0.616 | ||
No | 97 (97.98) | 102 (99.03) | |
Yes | 2 (2.02) | 1 (0.97) | |
Takes extra vitamin D | 0.850 | ||
No | 92 (92.93) | 95 (92.23) | |
Yes | 7 (7.07) | 8 (7.77) |
